MBRX News and Press, Moleculin Biotech Inc. From 02/01/21

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial Annamycin being used to target soft tissue sarcoma lung metastases PR Newswire HOUSTON , Feb. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or t...

Moleculin Biotech (MBRX) traded 6.7% down premarket after announcing a 1:6 reverse stock split of its common stock, effective Jan.29 after market close.Post the reverse stock split, outstanding shares will be reduced from ~72M shares to ~12M shares while authorized shares ...

Moleculin Announces Reverse Stock Split PR Newswire HOUSTON , Jan. 29, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...

Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference PR Newswire HOUSTON , Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of dr...

The FDA has granted an Orphan Drug Designation ((ODD)) to Moleculin Biotech's (MBRX) Annamycin for treatment of soft tissue sarcomas. Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.Also, the Agency has recently...

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas PR Newswire HOUSTON , Dec. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broa...

Palm Beach, FL – December 17, 2020 – Soft tissue sarcoma (STS) is a rare type of cancer that develops in tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occurring in the muscles, tissues, and blood vessels that protect, support and surroun...

Moleculin Biotech (MBRX) perks 3% premarket after FDA signed off Investigational New Drug application for Annamycin for the treatment of soft tissue sarcoma lung metastases.This allows Moleculin to begin a Phase 1B/2 clinical trial in the U.S. for patients with soft tissue...

Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases HOUSTON , Dec. 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broa...

Palm Beach, FL – December 3, 2020 – Acute myeloid leukemia (AML) is a rare and heterogeneous blood cancer with a poor overall prognosis. It affects predominantly older adults with a median age at diagnosis of 66 years but also includes about 15% of children from birth to 19 ye...